Expression of estrogen receptor beta isoforms in pancreatic adenocarcinoma
Metrics: PDF 543 views | HTML 875 views | ?
Mamoun Younes1, Charles J. Ly1, Kanchan Singh2, Atilla Ertan2, Pamela S. Younes1 and Jennifer M. Bailey2
1Departments of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA
2Department of Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA
Mamoun Younes, email: firstname.lastname@example.org
Keywords: estrogen receptor; proliferative activity; quantitative biomarker analysis; image analysis; pancreas
Received: August 29, 2018 Accepted: December 13, 2018 Published: December 28, 2018
Limited studies have shown that some patients with pancreatic adenocarcinoma (PAC) may benefit from treatment with tamoxifen. PAC has been shown to be largely negative for estrogen receptor alpha (ER-alpha). The aim of this pilot study was to investigate ER-beta expression in human PAC. Sections of tissue microarray with 18 evaluable cases of human PAC were stained by immunohistochemistry (IHC) for ER-beta1, ER-beta2, ER-beta5, and Cyclin A. The levels of ER-beta isoform expression and the S-phase fraction (SPF) were determined using quantitative digital image analysis.
Higher mean and median ER-beta2 levels correlated with male sex (p = 0.057 and p = 0.035, respectively), older age (p = 0.005 and p = 0.006, respectively), and lower pT stage (p = 0.008 and p = 0.009). Mean and median ER-beta5 levels correlated negatively with SPF (p = 0.021 and p = 0.047, respectively). Mean ER-beta1 expression did not correlate with any of the above mentioned clinicopathologic factors. The findings in this pilot study, although should be considered preliminary, suggest that some ER-beta isoforms may play a role in the biology of PAC. Additional larger studies are needed to confirm our findings, and to determine whether ER-beta may be considered for future targeted therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.